## Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

## **Listing of Claims:**

In the claims:

 (Original) An N-[(piperazinyl)hetaryl]arylsulfonamide compound of the general formula I

$$R^{1}-N$$
 $N-Q-R-SO_{2}-Ar$ 
 $(I)$ 

in which

- R is oxygen, a group N-R<sup>3</sup> or a group CR<sup>3a</sup>R<sup>3b</sup>;
- Q is a bivalent, 6-membered heteroaromatic radical which possesses 1 or 2

  N atoms as ring members and which optionally carries one or two substituents R<sup>a</sup> which is/are selected, independently of each other, from halogen, CN, NO<sub>2</sub>, CO<sub>2</sub>R<sup>4</sup>, COR<sup>5</sup>, C<sub>1</sub>-C<sub>4</sub>-alkyl, C<sub>1</sub>-C<sub>4</sub>-alkoxy, C<sub>1</sub>-C<sub>4</sub>-haloalkyl, NH<sub>2</sub>, NHR<sup>6</sup>, NR<sup>6</sup>R<sup>7</sup> and C<sub>1</sub>-C<sub>4</sub>-haloalkoxy;

4

Ar is phenyl or a 6-membered heteroaromatic radical which possesses 1 or 2 N atoms as ring members and which optionally carries one or two substituents R<sup>b</sup>, which is/are selected from halogen, NO<sub>2</sub>, CN, CO<sub>2</sub>R<sup>4</sup>, COR<sup>5</sup>, NH<sub>2</sub>, NHR<sup>6</sup>, NR<sup>6</sup>R<sup>7</sup>, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>1</sub>-C<sub>6</sub>-haloalkyl, C<sub>1</sub>-C<sub>6</sub>-alkoxy, C<sub>1</sub>-C<sub>6</sub>s22 -haloalkoxy, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl, C<sub>3</sub>-C<sub>6</sub>-cycloalkyl, C<sub>3</sub>-C<sub>6</sub>-cycloalkyl-C<sub>1</sub>-C<sub>4</sub>-alkyl and C<sub>1</sub>-C<sub>4</sub>-haloalkyl, with it also being possible for two radicals R<sup>b</sup> which are bonded to adjacent C atoms of Ar to be together C<sub>3</sub>-C<sub>4</sub>-alkylene;

n is 0, 1 or 2;

R<sup>1</sup> is hydrogen,  $C_1$ - $C_4$ -alkyl,  $C_1$ - $C_4$ -haloalkyl,  $C_3$ - $C_6$ -cycloalkyl,  $C_3$ - $C_6$ -cycloalkyl- $C_1$ - $C_4$ -alkyl,  $C_1$ - $C_4$ -hydroxyalkyl,  $C_1$ - $C_4$ -alkoxy- $C_1$ - $C_4$ -alkyl,  $C_3$ - $C_4$ -alkenyl or  $C_3$ - $C_4$ -alkynyl;

 $R^2$  is  $C_1$ - $C_4$ -alkyl or, together with  $R^1$ , is  $C_2$ - $C_5$ -alkylene or, in the case of n = 2, the two radicals  $R^2$  can together be  $C_1$ - $C_4$ -alkylene;

 $R^3$  is hydrogen or  $C_1$ - $C_4$ -alkyl;

R<sup>3a</sup>, R<sup>3b</sup> are, independently of each other, hydrogen or C<sub>1</sub>-C<sub>4</sub>-alkyl;

- R<sup>4</sup> is  $C_1$ - $C_4$ -alkyl,  $C_1$ - $C_4$ -haloalkyl,  $C_2$ - $C_4$ -alkenyl  $C_3$ - $C_6$ -cycloalkyl,  $C_3$ - $C_6$ -cycloalkyl- $C_1$ - $C_4$ -alkyl, phenyl or benzyl; and
- R<sup>5</sup> is hydrogen, C<sub>1</sub>-C<sub>4</sub>-alkyl, C<sub>1</sub>-C<sub>4</sub>-haloalkyl, C<sub>2</sub>-C<sub>4</sub>-alkenyl C<sub>3</sub>-C<sub>6</sub>-cycloalkyl, C<sub>3</sub>-C<sub>6</sub>-cycloalkyl-C<sub>1</sub>-C<sub>4</sub>-alkyl, phenyl or benzyl;
- R<sup>6</sup>, R<sup>7</sup> are each independently selected from C<sub>1</sub>-C<sub>4</sub>-alkyl, C<sub>1</sub>-C<sub>4</sub>-haloalkyl or together with the nitrogen to which they are bound form a saturated 3-, 4-, 5- or 6-membered heterocycle, which additionally may comprise an oxygen atom or an additional nitrogen atom as a ring member and which may carry 1, 2, 3 or 4 C<sub>1</sub>-C<sub>4</sub> alkyl groups;

the N-oxides thereof and the physiologically tolerated acid addition salts of these compounds;

with the exception of the compounds: 4-methyl-N-[6-(4-methylpiperazin-1-yl)pyridin-3-yl)benzenesulfonamide and 4-chloro-N-[6-(4-methylpiperazin-1-yl)pyridin-3-yl)benzenesulfonamide.

- 2. (Original) The compound as claimed in claim 1, wherein R is N-R<sup>3</sup> with R<sup>3</sup> being H or  $C_1$ - $C_4$ -alkyl.
- 2 3. (Currently Amended) The compound as claimed in claim 2, wherein
  - Q is a bivalent, 6-membered heteroaromatic radical which possesses 1 or 2 N atoms as ring members and which optionally carries one or two substituents

 $R^a$  which is/are selected, independently of each other, from halogen, CN,  $NO_2$ ,  $CO_2R^4$ ,  $COR^5$ ,  $C_1$ - $C_4$ -alkyl and  $C_1$ - $C_4$ -haloalkyl and

Ar is phenyl or a 6-membered heteroaromatic radical which possesses 1 or 2 N atoms as ring members and which optionally carries one or two substituents R<sup>b</sup>, which is/are selected from halogen, NO<sub>2</sub>, CN, CO<sub>2</sub>R<sup>4</sup>, COR<sup>5</sup>, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl, C<sub>3</sub>-C<sub>6</sub>-cycloalkyl, C<sub>3</sub>-C<sub>6</sub>-cycloalkyl-C\pard plain <sub>1</sub>-C<sub>4</sub>-alkyl and C<sub>1</sub>-C<sub>4</sub>-haloalkyl, with it also being possible for two radicals R<sup>b</sup> which are bonded to adjacent C atoms of Ar to be together C<sub>3</sub>-C<sub>4</sub>-alkylene.

- 3 <u>4</u>. (Currently Amended) The compound as claimed in claim 1, in which the piperazine ring is bonded to the heteroaromatic radical Q in the para position in relation to the group R-SO<sub>2</sub>-Ar.
- -4 <u>5</u>. (Currently Amended) The compound as claimed in <del>one of the preceding claims</del> <u>claim 1</u>, in which Q is a radical of the formula

$$A_{3}^{=}A_{2}$$

$$A_{3}^{-}$$

$$(R^{a})$$

in which  $A_1$ ,  $A_2$  and  $A_3$  are, independently of each other, N or CH, one or two of the variables  $A_1$ ,  $A_2$  and  $A_3$  can also be C-R<sup>a</sup>, k = 0 or 1 and R<sup>a</sup> is selected from halogen, C<sub>1</sub>-C<sub>4</sub>-alkyl, C<sub>1</sub>-C<sub>4</sub>-haloalkyl, C<sub>1</sub>-C<sub>4</sub>-alkoxy, NH<sub>2</sub>, NHR<sup>6</sup>, NR<sup>6</sup>R<sup>7</sup>s22 and C<sub>1</sub>-C<sub>4</sub>-haloalkoxy, with  $A_1$ ,  $A_2$  and  $A_3$  not simultaneously being N or simultaneously being selected from CH and C-R<sup>a</sup>.

5 <u>6</u>. (Currently Amended) The compound as claimed in claim  $\pm 5$ , in which A<sub>3</sub> is nitrogen, A<sub>2</sub> is CH and A<sub>1</sub> is N or CH and wherein the piperazine radical is located in the 2 position.

- 6  $\underline{7}$ . (Currently Amended) The compound as claimed in claim 5  $\underline{6}$ , in which Q is pyridin-2,5-diyl which carries the piperazine radical in the 2 position.
- 7 8. (Currently Amended) The compound as claimed in claim  $\frac{5}{6}$ , in which Q is a radical of the formula

$$- \bigwedge_{1}^{A_{1}=A_{2}}$$

$$- \bigwedge_{R^{a}}$$

in which  $A_1$  and  $A_2$  are, independently of each other, N or CH and  $R^a$  is selected from ,  $C_1$ - $C_4$ -alkoxy, NH<sub>2</sub>, NHR<sup>6</sup>, NR<sup>6</sup>R<sup>7</sup> and  $C_1$ - $C_4$ -haloalkoxy.

- 8 9. (Currently Amended) The compound as claimed in claim 7 8, in which  $A_1$  is N or CH and  $A_2$  is CH and wherein the piperazine radical is located in the 2 position.
- 9 <u>10</u>. (Currently Amended) The compound as claimed in one of the preceding claims claim 1, in which the radical Ar carries a substituent R<sup>b</sup> in the para position and, where appropriate, a further substituent R<sup>b</sup> in the meta position or in the ortho position, in each case based on the binding site of the sulfonamide group.
- 40 11. (Currently Amended) The compound as claimed in one of the preceding claims claim 1, in which Ar is phenyl or pyridyl, which radicals possess, where appropriate, one or 2 R<sup>b</sup> substituents.
- 11 12. (Currently Amended) The compound as claimed in one of the preceding claims claim 1, in which R<sup>1</sup> is different from hydrogen and methyl.
- 12 13. (Currently Amended) The compound as claimed in claim 1 of the general formula

$$R^{1}-N \longrightarrow A_{1}^{A_{1}^{-}A_{2}} \longrightarrow N-SO_{2} \longrightarrow R^{b}$$

$$(R^{2})_{n} \qquad (R^{a})_{k} \qquad (Ia)$$

in which n, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>a</sup> and R<sup>b</sup> have the meanings given in claim 1 and in which either

 $A_1$ ,  $A_2$  and  $A_3$  are, independently of each other, N or CH and one or two of the variables  $A_1$ ,  $A_2$  and  $A_3$  can also be C-R<sup>a</sup>, with  $A_1$ ,  $A_2$  and  $A_3$  not simultaneously being N or simultaneously being selected from CH and C-R<sup>a</sup>,

X and Y are selected from CH, C-R<sup>b'</sup> and N, in which R<sup>b'</sup> is halogen, methyl, CN, difluoromethyl or trifluoromethyl, with X and Y not simultaneously being N or simultaneously being C-R<sup>b'</sup>, and

k is 0 or 1.

43 <u>14</u>. (Currently Amended) The compound of the formula Ia as claimed in claim <u>12 13</u>, in which k = 0, with  $A_1$ ,  $A_2$  and  $A_3$  being, independently of each other, N or CH and  $A_1$ ,  $A_2$  and  $A_3$  not simultaneously being N or simultaneously being CH.

14 <u>15</u>. (Currently Amended) The compound of the formula Ia as claimed in claim 13 <u>14</u>, in which  $A_1$  is CH or N,  $A_2$  is CH and  $A_3$  is N.

45 <u>16</u>. (Currently Amended) The compound of the formula Ia as claimed in claim <u>12 13</u>, in which k is 1,  $A_1$  is CH or N,  $A_2$  is CH and  $A_3$  is N, and  $R^a$  is selected from ,  $C_1$ - $C_4$ -alkoxy, NH<sub>2</sub>, NHR<sup>6</sup>, NR<sup>6</sup>R<sup>7</sup> and  $C_1$ - $C_4$ -haloalkoxy and  $R^a$  is bound to the carbon atom adjacent to  $A_3$ .

16 <u>17</u>. (Currently Amended) The compound of the formula Ia as claimed in any of claims 12 to 15 claim 13, in which n is 0 or 1 and, in the case of n = 1,  $R^2$  is bonded to the C

atom of the piperazine ring which is adjacent to the group R<sup>1</sup>-N and is a methyl group having the S configuration.

17 18. (Currently Amended) The compound of the formula Ia as claimed in one of claims 12 to 16 claim 13, in which the radical Ar carries a substituent R<sup>b</sup> in the para position and, where appropriate, a further substituent R<sup>b</sup> in the meta position or in the ortho position, in each case based on the binding site of the sulfonamide group.

18 19. (Currently Amended) The compound of the formula Ia as claimed in one of claims 12 to 17 claim 13, in which Ar is phenyl or pyridyl, which radicals possess, where appropriate, one or 2 R<sup>b</sup> substituents.

49 <u>20</u>. (Currently Amended) The compound of the formula Ia as claimed in <del>one of claims 12 to 18</del> <u>claim 13</u>, in which R<sup>1</sup> is different from hydrogen and methyl.

20 21. (Currently Amended) The compound of the formula la as claimed in ene of claims 12 to 19 claim 13, of the general formula la.1

$$R^{1}-N \longrightarrow N \longrightarrow N \longrightarrow N \longrightarrow R^{3}$$

$$(R^{2})_{n} \qquad (R^{a})_{n}$$

$$(R^{a})_{n} \qquad (R^{a})_{n}$$

$$(Ia.1)$$

in which n, X, Y,  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^a$  and  $R^b$  have the meanings given in claim  $\frac{12}{13}$  and q is 0, 1 or 2.

21 22. (Currently Amended) The compound of the formula la as claimed in ene of claims 12 to 19, claim 13 of the general formula la.2

$$R^{1}-N \longrightarrow N \longrightarrow N \longrightarrow N \longrightarrow R^{3}$$

$$(R^{2})_{n} \qquad (R^{a})_{q} \qquad (Ia.2)$$

in which n, X, Y,  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^a$  and  $R^b$  have the meanings given in claim  $\frac{12}{13}$  and q is 0 or 1.

22 23. (Currently Amended) A pharmaceutical composition which comprises at least one N-[(piperazinyl)hetaryl]arylsulfonamide compound as claimed in one of claims 1 to 24 claim 1 and/or at least one physiologically tolerated acid addition salt of I and/or an N-oxide of I, where appropriate together with physiologically acceptable carriers and/or auxiliary substances.

23 24. (Currently Amended) The use of at least one N-[(piperazinyl)hetaryl]arylsulfonamide compound of the formula I

$$R^{1} - N \longrightarrow N - Q - N - SO_{2} - Ar$$

$$(I)$$

$$(R^{2})_{n}$$

in which Q, Ar, n, R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> have the previously mentioned meanings, of the N-oxides thereof and of the physiologically tolerated acid addition salts thereof for producing a pharmaceutical composition for treating diseases which respond to influencing by dopamine D<sub>3</sub> receptor antagonists or dopamine D<sub>3</sub> agonists.

24  $\underline{25}$ . (Currently Amended) The use as claimed in claim 23  $\underline{24}$  for treating diseases of the central nervous system.

25 <u>26</u>. (Currently Amended) The use as claimed in claim <del>23</del> 24 for treating kidney function disturbances.

26 <u>27</u>. (Currently Amended) A method for treating a medical disorder susceptible to treatment with a dopamine D<sub>3</sub> receptor antagonist or a dopamine D<sub>3</sub> agonist, said method comprising administering an effective amount of at least one compound of the formula I in which Q, Ar, n, R<sup>4</sup>, R<sup>2</sup> and R<sup>3</sup> have the previously mentioned meanings, or the N-oxides thereof or the physiologically tolerated acid addition salts thereof to claim 1

$$R^{1} - N \longrightarrow N - Q - N - SO_{2} - Ar$$
 (I)

to a subject in need thereof.

- 27 28. (Currently Amended) The method as claimed in Claim 26 claim 27, wherein the medical disorder is a disease of the central nervous system.
- 29. (New) The method as claimed in claim 27 wherein the medical disorder is a disturbance of kidney function.